RPTXライブシグナル | Getagraph.comで利益を最大化

買う 109568 min ago

@ $7.51

発行日: 13 2月 2024 @ 23:30

リターン: -57.39%

前回のシグナル: 2月 12 - 23:40

前回のシグナル: 売る

リターン: -7.28 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:32):

Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States...

Stats
本日の出来高	18 112.00
平均出来高	130 898
時価総額	134.98M
EPS	$0 ( 2024-02-27 )
次の収益日	( $-0.100 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.430
ATR14	$0.0150 (0.47%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Segal Lloyd Mitchell	Sell	2 650	Common Shares
2024-04-01	Segal Lloyd Mitchell	Sell	2 491	Common Shares
2024-03-28	Forte Steve	Sell	825	Common Shares
2024-04-01	Forte Steve	Sell	789	Common Shares
2024-03-28	Zinda Michael	Sell	450	Common Shares

INSIDER POWER
69.42
Last 99 transactions
Buy: 4 214 315 \| Sell: 3 499 776

ボリューム相関

長: -0.07 (neutral)

短: 0.34 (neutral)

Signal:(45.604) Neutral

Repare Therapeutics Inc. 相関

10 最も正の相関
AYTU	0.905
RPRX	0.905
RMCF	0.901
ALRS	0.897
HFWA	0.896
LBPS	0.894
TRIT	0.894
AMRB	0.892
RBB	0.89
BMRA	0.886

10 最も負の相関
DAKT	-0.913
CVT	-0.905
GBRG	-0.905
CMPO	-0.903
RAM	-0.899
DUOL	-0.897
VRIG	-0.894
BWMX	-0.893
BRACU	-0.882
HROW	-0.881

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Repare Therapeutics Inc. 相関 - 通貨/商品

-0.33
( neutral )

-0.32
( neutral )

0.00
( neutral )

-0.68
( moderate negative )

0.64
( weak )

0.12
( neutral )

Repare Therapeutics Inc. 財務諸表

Annual	2023
収益:	$51.13M
総利益:	$49.18M (96.18 %)
EPS:	$-2.23

FY	2023
収益:	$51.13M
総利益:	$49.18M (96.18 %)
EPS:	$-2.23

FY	2022
収益:	$131.83M
総利益:	$127.65M (96.83 %)
EPS:	$-0.690

FY	2021
収益:	$7.60M
総利益:	$7.60M (100.00 %)
EPS:	$-2.97

Financial Reports:

No articles found.

Repare Therapeutics Inc.

Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.